Insulinoma Workup

Overview

Insulinoma is the most common functional pancreatic endocrine neoplasm. Key facts:

90% are benign, solitary, sporadic adenomas
10% are malignant (lymph node or liver metastases)
10% are associated with MEN-1 (often multifocal, higher recurrence)
Evenly distributed: 1/3 head/uncinate, 1/3 body, 1/3 tail
<3% are ectopic (peripancreatic region)

Step 1 — Clinical Suspicion

Whipple's Triad

Symptoms of hypoglycemia during fasting
Documented serum glucose <50 mg/dL
Relief of symptoms after glucose administration

Symptoms

Category	Examples
Neuroglycopenic	Confusion, seizure, obtundation, personality change, coma, diplopia, weakness, amnesia
Adrenergic	Diaphoresis, trembling, palpitations, tachycardia

Patients often learn to eat frequently to abort symptoms → weight gain/obesity is common. Symptoms can persist years before diagnosis.

Step 2 — Biochemical Confirmation

Initial Labs

Fasting glucose + fasting insulin — if combined, insulin is inappropriately elevated in ~65% of insulinoma patients after overnight fast
C-peptide — elevated in endogenous insulin excess; normal/low if exogenous insulin self-administration
Proinsulin — elevated; most sensitive/specific criteria = fasting glucose <45 mg/dL + elevated proinsulin
Insulin-to-glucose ratio — >0.3 supports insulinoma (normal <0.3)

Surreptitious Use Exclusion

Cause	C-peptide	Other findings
Endogenous (insulinoma)	↑	↑ proinsulin
Exogenous insulin	Low/normal	Possible anti-insulin antibodies (bovine/porcine)
Oral hypoglycemics (sulfonylureas)	↑	Toxicology screen positive

Step 3 — Supervised 72-Hour Fast (Gold Standard Functional Test)

Blood sampled every 4–6 hours for glucose and insulin
Sample immediately when symptoms develop; stop test and give IV glucose
75–80% of insulinoma patients become symptomatic with glucose <40 mg/dL within 24 hours
~100% within 72 hours
Diagnostic criteria during fast:
- Glucose <40–50 mg/dL with concurrent insulin >25 µU/mL
- Insulin:glucose ratio >0.3

Must be done with close supervision — can be dangerous. — Schwartz's Principles of Surgery

Step 4 — Localization Imaging

Once biochemical diagnosis is confirmed, localize and stage:

First-Line

Modality	Notes
CT (multiphasic)	Standard first-line cross-sectional imaging
Endoscopic ultrasound (EUS)	>90% preoperative detection rate; highly sensitive for small pancreatic lesions

Second-Line / Adjunct

Modality	Indication
Ga-68 DOTATATE PET scan (somatostatin receptor imaging)	Not routine — use if metastases suspected or tumor occult on other imaging
Hepatic venous sampling after arterial calcium stimulation	Rare; reserved for truly occult insulinoma
Visceral angiography with venous sampling	Rarely required

Radioactive octreotide scan showing pancreatic endocrine tumor in the body of the pancreas

Radioactive octreotide scan demonstrating a pancreatic endocrine tumor in the body of the pancreas — Schwartz's Principles of Surgery

Step 5 — MEN-1 Workup

Screen for MEN-1 in all patients (esp. if multifocal tumors found on imaging or family history)
MEN-1-associated insulinomas: more likely multifocal, higher surgical recurrence
Check: serum calcium, PTH, pituitary MRI, parathyroid evaluation

Summary Algorithm

Clinical suspicion (Whipple's Triad)
         ↓
Fasting glucose + insulin + C-peptide + proinsulin
         ↓
Exclude exogenous causes (C-peptide low → exogenous insulin; toxicology → sulfonylureas)
         ↓
72-hour supervised fast (if biochemistry inconclusive)
         ↓
Biochemical confirmation → Localization
         ↓
CT (multiphasic) + EUS
         ↓
If occult: Ga-68 DOTATATE PET or arterial calcium stimulation/venous sampling
         ↓
Screen for MEN-1 if multifocal or familial
         ↓
Surgical resection (enucleation, distal pancreatectomy, or pancreaticoduodenectomy)

Sources: Mulholland and Greenfield's Surgery 7e, Schwartz's Principles of Surgery 11e, Sleisenger and Fordtran's GI and Liver Disease

This is a shared conversation. Sign in to Orris to start your own chat.